Shell Asset Management Co. Decreases Holdings in Emergent BioSolutions Inc. (NYSE:EBS)

Shell Asset Management Co. lessened its holdings in shares of Emergent BioSolutions Inc. (NYSE:EBSGet Rating) by 12.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,495 shares of the biopharmaceutical company’s stock after selling 1,848 shares during the quarter. Shell Asset Management Co.’s holdings in Emergent BioSolutions were worth $513,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of EBS. Eaton Vance Management boosted its stake in Emergent BioSolutions by 39.8% in the fourth quarter. Eaton Vance Management now owns 2,745 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 782 shares in the last quarter. Cutler Group LP boosted its stake in Emergent BioSolutions by 250.0% in the first quarter. Cutler Group LP now owns 700 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 500 shares in the last quarter. Covestor Ltd purchased a new stake in Emergent BioSolutions in the fourth quarter worth approximately $49,000. Schroder Investment Management Group purchased a new stake in Emergent BioSolutions in the fourth quarter worth approximately $54,000. Finally, First Bank & Trust boosted its stake in Emergent BioSolutions by 32.3% in the fourth quarter. First Bank & Trust now owns 1,850 shares of the biopharmaceutical company’s stock worth $81,000 after buying an additional 452 shares in the last quarter. Institutional investors own 86.02% of the company’s stock.

Insiders Place Their Bets

In other Emergent BioSolutions news, Director Kathryn C. Zoon sold 1,173 shares of the stock in a transaction on Thursday, June 9th. The stock was sold at an average price of $31.52, for a total value of $36,972.96. Following the completion of the transaction, the director now owns 19,654 shares in the company, valued at $619,494.08. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Emergent BioSolutions news, Director Kathryn C. Zoon sold 1,173 shares of the stock in a transaction on Thursday, June 9th. The stock was sold at an average price of $31.52, for a total value of $36,972.96. Following the completion of the transaction, the director now owns 19,654 shares in the company, valued at $619,494.08. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Kathryn C. Zoon sold 1,996 shares of the stock in a transaction on Tuesday, May 24th. The stock was sold at an average price of $35.53, for a total value of $70,917.88. Following the completion of the sale, the director now directly owns 12,381 shares in the company, valued at $439,896.93. The disclosure for this sale can be found here. 11.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have issued reports on EBS. Cantor Fitzgerald lowered Emergent BioSolutions from an “overweight” rating to a “neutral” rating in a research note on Friday, April 29th. Cowen lowered their price objective on Emergent BioSolutions from $40.00 to $30.00 in a research report on Friday, April 29th. Wells Fargo & Company lowered their price objective on Emergent BioSolutions from $46.00 to $38.00 in a research report on Wednesday, May 4th. Cowen lowered their price objective on Emergent BioSolutions from $40.00 to $30.00 in a research report on Friday, April 29th. Finally, StockNews.com downgraded Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Saturday, May 7th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, Emergent BioSolutions presently has an average rating of “Hold” and a consensus target price of $49.17.

Emergent BioSolutions Price Performance

Shares of Emergent BioSolutions stock opened at $30.72 on Thursday. The company has a quick ratio of 2.81, a current ratio of 4.42 and a debt-to-equity ratio of 0.51. The company has a market cap of $1.54 billion, a PE ratio of 18.18 and a beta of 0.98. The business has a 50 day moving average of $31.70 and a 200 day moving average of $37.36. Emergent BioSolutions Inc. has a 52 week low of $26.85 and a 52 week high of $65.09.

Emergent BioSolutions (NYSE:EBSGet Rating) last announced its earnings results on Monday, August 1st. The biopharmaceutical company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of $0.38 by ($1.24). The business had revenue of $242.70 million for the quarter, compared to the consensus estimate of $268.77 million. Emergent BioSolutions had a net margin of 6.02% and a return on equity of 12.11%. Emergent BioSolutions’s revenue was down 38.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.33 EPS. As a group, equities research analysts forecast that Emergent BioSolutions Inc. will post 1.02 earnings per share for the current year.

Emergent BioSolutions Company Profile

(Get Rating)

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care.

Read More

Institutional Ownership by Quarter for Emergent BioSolutions (NYSE:EBS)

Want More Great Investing Ideas?

Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.